Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Basket Trial of IO102-IO103 + Pembrolizumab in First-line Metastatic NSCLC, SCCHN, and Urothelial Bladder Cancer
2024-511561-10-00Phase 2Completed
- Sponsor
- IO Biotech
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of PD-L1/IDO peptide vaccine and pembrolizumab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), transitional cell carcinoma of the bladder (TCC) and 3 more (3 cohorts), sponsored by IO Biotech. Primary endpoint: Overall objective response rate (ORR) according to RECIST v1.1. Started Feb 2024; status: completed.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma of the bladder (TCC)Renal pelvis urothelial carcinoma (UTUC)ureteral urothelial carcinoma
Beyond the preview
Go deeper on 2024-511561-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511561-10-00.